SlideShare una empresa de Scribd logo
1 de 14
FDA 483 Observations
Resolving the Issues
Compliance Insight, Inc. 513-860-3512 Copyrighted 2013
What to do now?
If you are reading this now, you are probably in the middle of
some sort of FDA enforcement issue. Responding to FDA 483
observations can be one of the most important, and most
challenging, activities in your career and the company’s
history.
Failure to ensure a proper response and failing to clearly
indicate to the FDA that you are in CONTROL can be fatal to
your business.
Writing the Response – 14 Points
There are some basic rules that can be
established regarding writing a response
letter.
Some or all of these rules may apply
depending upon the particular situation of
the firm – e.g. lengthy list of observations
from a governmental body, client audit,
warning letter pending, etc.
14 Points to Success
1. Someone in a high level in the Quality Department should
write the response.
2. Personnel copied on the response should include high-
level management. This shows that management at the
firm is aware of the issues and the commitments being
made.
3. Include a cover letter or opening statement. Thank the
auditor(s) for being professional, providing insight or
other appropriate remarks as warranted. State the site
address of the audit and the dates.
4. Always remember that you are writing the response to
the auditor’s management – governmental auditing
bodies as well as clients. Do not assume that the person
reading the report understands the context of the
observation or your reply.
14 Points to Success
5. Re-state the observation and reference number in the
response. Typically, the observation goes directly above
the response.
6. If possible, indicate the related compliant systems. This
shows that you are in control and that some operations
were functioning within acceptable GMP parameters.
7. If the action item is going to take some time to
implement, state what will be done in the interim to be
compliant with GMPs? Don’t simply indicate that actions
will be taken in six months to correct the issue in which
you are currently out of compliance without addressing
what you will do to be compliant from the current date
until the corrections are implemented.
14 Points to Success
8. If corrective actions have already taken place, indicate the
following:
• Dates implemented
• Training performed (copies of training sign-up
sheets included)
• Copies of Purchase Orders, installation work,
etc.
• Copies of updated SOPs – indicating what was
changed.
9. Define how enhancements will prevent recurrence of the
issue observed. Don’t assume that the reader will
understand this fact.
10. Explain what will be done to expand, enhance or
streamline the compliance system.
14 Points to Success
11. Don’t forget about training. Allow sufficient time to
implement changes to incorporate training that may
include proficiency testing.
12. Describe how the firm will monitor the progress and
effectiveness of the corrective actions.
13. It may be helpful to explain that despite the issues noted,
there has never been an issue. It is not advisable to use
this response tactic each time but it can be advantageous
for critical observations to state something on the order
of “…the product has always met predetermined quality
parameters…”
14. Revise, revise, revise. Allow other people not directly
involved with the audit to review and comment on the
response. They may have insight on response wording
that would assist in clarification or strengthening of
points.
7 Actions to Avoid
Although the following information is not an exhaustive list,
there are some strategies taken by firms that indicate to an
auditor the firm’s unwillingness to change or inability to make
appropriate corrective actions.
If a firm does not have the capability, time or experience to
respond appropriately to an audit (especially a government
audit), a prime directive should be to seek outside assistance.
AVOID – At all costs!
Pathway to Disaster
1. During the closeout or in the response letter, argue every
point in that “they are not appropriate” or “we have
never had an issue with this point from other auditors”.
This is called a “scorched earth” policy and will ensure
that the auditor has a strong message of non-compliance
to the auditor body.
2. State that the corrective actions being requested will “put
the firm out of business” or “drive jobs to a foreign
country”. It is a scare tactic that has been used for at
least 20 years and has not proven to be the case.
3. The “rain forest” or overwhelming response. Include
massive amounts of data that is not warranted with the
hopes that the reviewer will be “impressed” with the
work. This type of response sends an immediate warning
signal to the auditor that issues are being glossed over.
Pathway to Disaster
4. Implement changes immediately. Either during
the closeout meeting or with a quick response,
all changes have been implemented for complex
issues. If the issue is simple, great – no
problem. However, for complex observations, a
rapid response indicates that the firm has taken
a knee-jerk reaction and implemented
corrective actions without thinking of the root
cause.
5. Not responding to the audit. Actions may be
taken but no formal letter is sent indicating
what was performed. This approach indicates
that the firm does not take the audit seriously.
Pathway to Disaster
6. The enigmatic response. The firm indicates that
actions are going to be taken but does not
address what these actions include. Such an
example would include: Actions Taken –
Records were updated. When? How were they
updated?
7. Promise without substance. Similar to the
enigmatic response, this approach does not
indicate any specifics. An example includes:
Deficiency – Detailed investigation not
performed in a timely manner. Response –
Investigations will be carried out in a timely
manner.
Assess Systemically
Resolve Issues or Plan to Resolve –
Systemically, across all sites
Finish the Response – If serious enough,
follow-up with your district office
Verify – that the resolutions worked
The FDA 483 – Phases to Resolve
Phase 4
Phase 1
Phase 2
Phase 3
The Choice is Yours!
Work diligently now or face serious issues
in the future
Questions? More Information?
Compliance Insight, Inc.
www.Compliance-Insight.com
513-860-3512
FDA483Team@Compliance-Insight.com
We have a significant source of information to help you on
dealing FDA 483’s – Contact us for a free consultation.

Más contenido relacionado

La actualidad más candente

FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letterSridhar S
 
Center for Biologics Evaluation and Research
Center for Biologics Evaluation and ResearchCenter for Biologics Evaluation and Research
Center for Biologics Evaluation and ResearchRajeswariS12
 
Quality Systems Approach to Pharmaceutical cGMP
Quality Systems Approach to Pharmaceutical cGMPQuality Systems Approach to Pharmaceutical cGMP
Quality Systems Approach to Pharmaceutical cGMPReddy N
 
21 cfr part 210 and 211
21 cfr part 210 and 21121 cfr part 210 and 211
21 cfr part 210 and 211Bhanu Chava
 
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning Letters
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning LettersHow to Prepare for an FDA Inspection and Respond to FDA 483's / Warning Letters
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning LettersGreenlight Guru
 
Investigation of OOS and OOT results
Investigation of OOS and OOT resultsInvestigation of OOS and OOT results
Investigation of OOS and OOT resultsMoshfiqur Rahaman
 
GMP Training: Handling of deviation
GMP Training: Handling of deviationGMP Training: Handling of deviation
GMP Training: Handling of deviationDr. Amsavel A
 
21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)AshishVerma593
 
OUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptxOUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptxMohamed Fazil M
 

La actualidad más candente (20)

Fda Inspection
Fda InspectionFda Inspection
Fda Inspection
 
Doc in pharma
Doc in pharmaDoc in pharma
Doc in pharma
 
21 cfr, parts 210 211
21 cfr, parts 210 21121 cfr, parts 210 211
21 cfr, parts 210 211
 
FDA Warning letter
FDA Warning letterFDA Warning letter
FDA Warning letter
 
Handling of Out of Specification Results
Handling of Out of Specification ResultsHandling of Out of Specification Results
Handling of Out of Specification Results
 
Gamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash raGamp 5 overview by jaya prakash ra
Gamp 5 overview by jaya prakash ra
 
Center for Biologics Evaluation and Research
Center for Biologics Evaluation and ResearchCenter for Biologics Evaluation and Research
Center for Biologics Evaluation and Research
 
ICH Q7 Guideline
ICH Q7 GuidelineICH Q7 Guideline
ICH Q7 Guideline
 
Gamp5 new
Gamp5 newGamp5 new
Gamp5 new
 
FDA Inspection
FDA InspectionFDA Inspection
FDA Inspection
 
Quality Systems Approach to Pharmaceutical cGMP
Quality Systems Approach to Pharmaceutical cGMPQuality Systems Approach to Pharmaceutical cGMP
Quality Systems Approach to Pharmaceutical cGMP
 
ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10ICH Guidelines Q1 - Q10
ICH Guidelines Q1 - Q10
 
21 cfr part 210 and 211
21 cfr part 210 and 21121 cfr part 210 and 211
21 cfr part 210 and 211
 
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning Letters
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning LettersHow to Prepare for an FDA Inspection and Respond to FDA 483's / Warning Letters
How to Prepare for an FDA Inspection and Respond to FDA 483's / Warning Letters
 
Investigation of OOS and OOT results
Investigation of OOS and OOT resultsInvestigation of OOS and OOT results
Investigation of OOS and OOT results
 
GMP Training: Handling of deviation
GMP Training: Handling of deviationGMP Training: Handling of deviation
GMP Training: Handling of deviation
 
Out of specifications
Out of specificationsOut of specifications
Out of specifications
 
21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)21 Code of Federal Regulation(21-CFR)
21 Code of Federal Regulation(21-CFR)
 
OUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptxOUT OF SPECIFICATIONS (OOS).pptx
OUT OF SPECIFICATIONS (OOS).pptx
 
Snda
SndaSnda
Snda
 

Destacado

Responding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning LettersResponding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning LettersMaetrics
 
FDA Form 483 (Inspectional Observations) - Top Violations 2013
FDA Form 483 (Inspectional Observations) - Top Violations 2013FDA Form 483 (Inspectional Observations) - Top Violations 2013
FDA Form 483 (Inspectional Observations) - Top Violations 2013Marc Sanchez
 
Form 483 Ranbaxy (Mohali Facility)
Form 483  Ranbaxy (Mohali Facility)Form 483  Ranbaxy (Mohali Facility)
Form 483 Ranbaxy (Mohali Facility)Gaurav kumar
 
Responding To A 483and Warning Letter
Responding To A 483and Warning LetterResponding To A 483and Warning Letter
Responding To A 483and Warning LetterJohn E. Osani
 
Inspection by regulatory authority ( fda )
Inspection by regulatory authority (  fda )Inspection by regulatory authority (  fda )
Inspection by regulatory authority ( fda )aartipatil084
 
FDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptFDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptshaik malangsha
 
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6Rx Research Services CRO
 
PCrompton_Warning Letter Response
PCrompton_Warning Letter ResponsePCrompton_Warning Letter Response
PCrompton_Warning Letter ResponsePhilip Crompton
 
Fda warning letter 3 5-2013 to dialysis drug maker and dialysis provider Fres...
Fda warning letter 3 5-2013 to dialysis drug maker and dialysis provider Fres...Fda warning letter 3 5-2013 to dialysis drug maker and dialysis provider Fres...
Fda warning letter 3 5-2013 to dialysis drug maker and dialysis provider Fres...Michael J. Evans
 
Mock Response to a FDA Warning Letter
Mock Response to a FDA Warning LetterMock Response to a FDA Warning Letter
Mock Response to a FDA Warning Lettermuna_ali
 
FDA 2013 Clinical Investigator Training Course: Roles and Responsibilities f...
FDA 2013 Clinical Investigator Training Course:  Roles and Responsibilities f...FDA 2013 Clinical Investigator Training Course:  Roles and Responsibilities f...
FDA 2013 Clinical Investigator Training Course: Roles and Responsibilities f...MedicReS
 
Ema fda joint inspections
Ema fda joint inspectionsEma fda joint inspections
Ema fda joint inspectionsVaska Toné
 

Destacado (17)

Responding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning LettersResponding Effectively to FDA 483 Observations & Warning Letters
Responding Effectively to FDA 483 Observations & Warning Letters
 
FDA Form 483 (Inspectional Observations) - Top Violations 2013
FDA Form 483 (Inspectional Observations) - Top Violations 2013FDA Form 483 (Inspectional Observations) - Top Violations 2013
FDA Form 483 (Inspectional Observations) - Top Violations 2013
 
Form 483 Ranbaxy (Mohali Facility)
Form 483  Ranbaxy (Mohali Facility)Form 483  Ranbaxy (Mohali Facility)
Form 483 Ranbaxy (Mohali Facility)
 
Responding To A 483and Warning Letter
Responding To A 483and Warning LetterResponding To A 483and Warning Letter
Responding To A 483and Warning Letter
 
FDA Warning Letter
FDA Warning LetterFDA Warning Letter
FDA Warning Letter
 
FDA Audit Prep
FDA Audit PrepFDA Audit Prep
FDA Audit Prep
 
Inspection by regulatory authority ( fda )
Inspection by regulatory authority (  fda )Inspection by regulatory authority (  fda )
Inspection by regulatory authority ( fda )
 
FDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).pptFDA Inspections ( How to Survive an FDA Inspection).ppt
FDA Inspections ( How to Survive an FDA Inspection).ppt
 
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6
Marlene Garcia Swider ASQ, PDA, SoCalBio Presentation Oct. 6
 
Fda warning letter
Fda warning letterFda warning letter
Fda warning letter
 
PCrompton_Warning Letter Response
PCrompton_Warning Letter ResponsePCrompton_Warning Letter Response
PCrompton_Warning Letter Response
 
Fda warning letter 3 5-2013 to dialysis drug maker and dialysis provider Fres...
Fda warning letter 3 5-2013 to dialysis drug maker and dialysis provider Fres...Fda warning letter 3 5-2013 to dialysis drug maker and dialysis provider Fres...
Fda warning letter 3 5-2013 to dialysis drug maker and dialysis provider Fres...
 
Mock Response to a FDA Warning Letter
Mock Response to a FDA Warning LetterMock Response to a FDA Warning Letter
Mock Response to a FDA Warning Letter
 
FDA 2013 Clinical Investigator Training Course: Roles and Responsibilities f...
FDA 2013 Clinical Investigator Training Course:  Roles and Responsibilities f...FDA 2013 Clinical Investigator Training Course:  Roles and Responsibilities f...
FDA 2013 Clinical Investigator Training Course: Roles and Responsibilities f...
 
Ema fda joint inspections
Ema fda joint inspectionsEma fda joint inspections
Ema fda joint inspections
 
Lyophiliser
LyophiliserLyophiliser
Lyophiliser
 
Excipient Auditing
Excipient AuditingExcipient Auditing
Excipient Auditing
 

Similar a FDA 483

FDA Inspections: Handling the Consequences. Dealing with the aftermath of an...
FDA Inspections: Handling the Consequences.  Dealing with the aftermath of an...FDA Inspections: Handling the Consequences.  Dealing with the aftermath of an...
FDA Inspections: Handling the Consequences. Dealing with the aftermath of an...Michael Swit
 
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...Michael Swit
 
10 Things an Operations Supervisor can do Today to Improve Reliability
10 Things an Operations Supervisor can do Today to Improve Reliability10 Things an Operations Supervisor can do Today to Improve Reliability
10 Things an Operations Supervisor can do Today to Improve ReliabilityRicky Smith CMRP, CMRT
 
Nadcap newsletter 1607-12 for website
Nadcap newsletter 1607-12 for websiteNadcap newsletter 1607-12 for website
Nadcap newsletter 1607-12 for websiteAdrien Boespflug
 
Corrective action training april 2013
Corrective action training april 2013Corrective action training april 2013
Corrective action training april 2013Doug Bryson
 
Effective Techniques For CM Implementation In Organizations
Effective Techniques For CM Implementation In OrganizationsEffective Techniques For CM Implementation In Organizations
Effective Techniques For CM Implementation In OrganizationsGroup50 Consulting
 
What is Remediation?
What is Remediation?What is Remediation?
What is Remediation?EMMAIntl
 
simplifying-capa-seven-steps.pdf
simplifying-capa-seven-steps.pdfsimplifying-capa-seven-steps.pdf
simplifying-capa-seven-steps.pdfqcsasib
 
Managing Staff Performance
Managing Staff PerformanceManaging Staff Performance
Managing Staff PerformanceSimeon Pashley
 
Anomalies, complaints and non-compliances
Anomalies, complaints and non-compliancesAnomalies, complaints and non-compliances
Anomalies, complaints and non-compliancesTim Sandle, Ph.D.
 
Question 11.  The difference between profit sharing and stock .docx
Question 11.  The difference between profit sharing and stock .docxQuestion 11.  The difference between profit sharing and stock .docx
Question 11.  The difference between profit sharing and stock .docxIRESH3
 
Choosing an alm tool set
Choosing an alm tool setChoosing an alm tool set
Choosing an alm tool setIan McDonald
 
Audit vs inspection
Audit vs inspectionAudit vs inspection
Audit vs inspectionmazrulazman
 
Employee progressive discipline
Employee progressive disciplineEmployee progressive discipline
Employee progressive disciplineSaxbee Consultants
 
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate ComplianceFDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate ComplianceMichael Swit
 
10 Principles Of Ops Management
10 Principles Of Ops Management10 Principles Of Ops Management
10 Principles Of Ops Managementrajjangupta
 

Similar a FDA 483 (20)

FDA Inspections: Handling the Consequences. Dealing with the aftermath of an...
FDA Inspections: Handling the Consequences.  Dealing with the aftermath of an...FDA Inspections: Handling the Consequences.  Dealing with the aftermath of an...
FDA Inspections: Handling the Consequences. Dealing with the aftermath of an...
 
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...FDA Warning Letters:  Key Legal and Tactical Issues in Dealing with FDA's "Sh...
FDA Warning Letters: Key Legal and Tactical Issues in Dealing with FDA's "Sh...
 
10 Things an Operations Supervisor can do Today to Improve Reliability
10 Things an Operations Supervisor can do Today to Improve Reliability10 Things an Operations Supervisor can do Today to Improve Reliability
10 Things an Operations Supervisor can do Today to Improve Reliability
 
Nadcap newsletter 1607-12 for website
Nadcap newsletter 1607-12 for websiteNadcap newsletter 1607-12 for website
Nadcap newsletter 1607-12 for website
 
Corrective action training april 2013
Corrective action training april 2013Corrective action training april 2013
Corrective action training april 2013
 
Effective Techniques For CM Implementation In Organizations
Effective Techniques For CM Implementation In OrganizationsEffective Techniques For CM Implementation In Organizations
Effective Techniques For CM Implementation In Organizations
 
Quality audit plan
Quality audit planQuality audit plan
Quality audit plan
 
Qsm guidelines
Qsm guidelinesQsm guidelines
Qsm guidelines
 
What is Remediation?
What is Remediation?What is Remediation?
What is Remediation?
 
simplifying-capa-seven-steps.pdf
simplifying-capa-seven-steps.pdfsimplifying-capa-seven-steps.pdf
simplifying-capa-seven-steps.pdf
 
Managing Staff Performance
Managing Staff PerformanceManaging Staff Performance
Managing Staff Performance
 
Anomalies, complaints and non-compliances
Anomalies, complaints and non-compliancesAnomalies, complaints and non-compliances
Anomalies, complaints and non-compliances
 
Audit of Your Franchise Audit Checklist
Audit of Your Franchise Audit ChecklistAudit of Your Franchise Audit Checklist
Audit of Your Franchise Audit Checklist
 
Question 11.  The difference between profit sharing and stock .docx
Question 11.  The difference between profit sharing and stock .docxQuestion 11.  The difference between profit sharing and stock .docx
Question 11.  The difference between profit sharing and stock .docx
 
Choosing an alm tool set
Choosing an alm tool setChoosing an alm tool set
Choosing an alm tool set
 
Audit vs inspection
Audit vs inspectionAudit vs inspection
Audit vs inspection
 
Disciplining
DiscipliningDisciplining
Disciplining
 
Employee progressive discipline
Employee progressive disciplineEmployee progressive discipline
Employee progressive discipline
 
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate ComplianceFDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
FDA’s New Strategy on Enforcement: The Growing Perils of Inadequate Compliance
 
10 Principles Of Ops Management
10 Principles Of Ops Management10 Principles Of Ops Management
10 Principles Of Ops Management
 

Más de Compliance Insight, Inc.

Más de Compliance Insight, Inc. (12)

July 2015
July 2015July 2015
July 2015
 
GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.GCP Overview by Compliance Insight, Inc.
GCP Overview by Compliance Insight, Inc.
 
FDA audit series part 5, dealing with the 483 or Warning Letter
FDA audit series   part 5, dealing with the 483 or Warning LetterFDA audit series   part 5, dealing with the 483 or Warning Letter
FDA audit series part 5, dealing with the 483 or Warning Letter
 
FDA audit series part 4, the closeout
FDA audit series   part 4, the closeoutFDA audit series   part 4, the closeout
FDA audit series part 4, the closeout
 
Fda audit series part 3, while the fda is there
Fda audit series   part 3, while the fda is  thereFda audit series   part 3, while the fda is  there
Fda audit series part 3, while the fda is there
 
FDA audit series part 2, what to do when the FDA arrives
FDA audit series   part 2, what to do when the FDA arrivesFDA audit series   part 2, what to do when the FDA arrives
FDA audit series part 2, what to do when the FDA arrives
 
FDA audit series part 1, Preparing for the Audit
FDA audit series   part 1, Preparing for the AuditFDA audit series   part 1, Preparing for the Audit
FDA audit series part 1, Preparing for the Audit
 
About Compliance Insight Inc.
About Compliance Insight Inc.About Compliance Insight Inc.
About Compliance Insight Inc.
 
Basics of FDA GMP Training
Basics of FDA GMP TrainingBasics of FDA GMP Training
Basics of FDA GMP Training
 
FDA Audit - The Do and Don't List
FDA Audit - The Do and Don't ListFDA Audit - The Do and Don't List
FDA Audit - The Do and Don't List
 
FDA GMP Training - The Quality Audit
FDA GMP Training - The Quality AuditFDA GMP Training - The Quality Audit
FDA GMP Training - The Quality Audit
 
Top 22 Tips: Writing For FDA Compliance
Top 22 Tips: Writing For FDA ComplianceTop 22 Tips: Writing For FDA Compliance
Top 22 Tips: Writing For FDA Compliance
 

Último

Over the Top (OTT) Market Size & Growth Outlook 2024-2030
Over the Top (OTT) Market Size & Growth Outlook 2024-2030Over the Top (OTT) Market Size & Growth Outlook 2024-2030
Over the Top (OTT) Market Size & Growth Outlook 2024-2030tarushabhavsar
 
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al MizharAl Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizharallensay1
 
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai KuwaitThe Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwaitdaisycvs
 
Falcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting
 
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSCROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSpanmisemningshen123
 
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in OmanMifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Omaninstagramfab782445
 
Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1kcpayne
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingNauman Safdar
 
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGParadip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGpr788182
 
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel
 
Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...
Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...
Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...ssuserf63bd7
 
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAIGetting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAITim Wilson
 
Rice Manufacturers in India | Shree Krishna Exports
Rice Manufacturers in India | Shree Krishna ExportsRice Manufacturers in India | Shree Krishna Exports
Rice Manufacturers in India | Shree Krishna ExportsShree Krishna Exports
 
PHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPanhandleOilandGas
 
Cannabis Legalization World Map: 2024 Updated
Cannabis Legalization World Map: 2024 UpdatedCannabis Legalization World Map: 2024 Updated
Cannabis Legalization World Map: 2024 UpdatedCannaBusinessPlans
 
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...Falcon Invoice Discounting
 
Falcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon investment
 
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...
joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...NadhimTaha
 
Falcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business GrowthFalcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business GrowthFalcon investment
 

Último (20)

Over the Top (OTT) Market Size & Growth Outlook 2024-2030
Over the Top (OTT) Market Size & Growth Outlook 2024-2030Over the Top (OTT) Market Size & Growth Outlook 2024-2030
Over the Top (OTT) Market Size & Growth Outlook 2024-2030
 
!~+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUD...
!~+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUD...!~+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUD...
!~+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUD...
 
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al MizharAl Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
Al Mizhar Dubai Escorts +971561403006 Escorts Service In Al Mizhar
 
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai KuwaitThe Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
The Abortion pills for sale in Qatar@Doha [+27737758557] []Deira Dubai Kuwait
 
Falcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investors
 
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NSCROSS CULTURAL NEGOTIATION BY PANMISEM NS
CROSS CULTURAL NEGOTIATION BY PANMISEM NS
 
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in OmanMifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
Mifepristone Available in Muscat +918761049707^^ €€ Buy Abortion Pills in Oman
 
Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1
 
Mckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for ViewingMckinsey foundation level Handbook for Viewing
Mckinsey foundation level Handbook for Viewing
 
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDINGParadip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
Paradip CALL GIRL❤7091819311❤CALL GIRLS IN ESCORT SERVICE WE ARE PROVIDING
 
Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024Marel Q1 2024 Investor Presentation from May 8, 2024
Marel Q1 2024 Investor Presentation from May 8, 2024
 
Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...
Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...
Horngren’s Cost Accounting A Managerial Emphasis, Canadian 9th edition soluti...
 
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAIGetting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
Getting Real with AI - Columbus DAW - May 2024 - Nick Woo from AlignAI
 
Rice Manufacturers in India | Shree Krishna Exports
Rice Manufacturers in India | Shree Krishna ExportsRice Manufacturers in India | Shree Krishna Exports
Rice Manufacturers in India | Shree Krishna Exports
 
PHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation FinalPHX May 2024 Corporate Presentation Final
PHX May 2024 Corporate Presentation Final
 
Cannabis Legalization World Map: 2024 Updated
Cannabis Legalization World Map: 2024 UpdatedCannabis Legalization World Map: 2024 Updated
Cannabis Legalization World Map: 2024 Updated
 
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...
Unveiling Falcon Invoice Discounting: Leading the Way as India's Premier Bill...
 
Falcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business PotentialFalcon Invoice Discounting: Unlock Your Business Potential
Falcon Invoice Discounting: Unlock Your Business Potential
 
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...
joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...joint cost.pptx  COST ACCOUNTING  Sixteenth Edition                          ...
joint cost.pptx COST ACCOUNTING Sixteenth Edition ...
 
Falcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business GrowthFalcon Invoice Discounting: Empowering Your Business Growth
Falcon Invoice Discounting: Empowering Your Business Growth
 

FDA 483

  • 1. FDA 483 Observations Resolving the Issues Compliance Insight, Inc. 513-860-3512 Copyrighted 2013
  • 2. What to do now? If you are reading this now, you are probably in the middle of some sort of FDA enforcement issue. Responding to FDA 483 observations can be one of the most important, and most challenging, activities in your career and the company’s history. Failure to ensure a proper response and failing to clearly indicate to the FDA that you are in CONTROL can be fatal to your business.
  • 3. Writing the Response – 14 Points There are some basic rules that can be established regarding writing a response letter. Some or all of these rules may apply depending upon the particular situation of the firm – e.g. lengthy list of observations from a governmental body, client audit, warning letter pending, etc.
  • 4. 14 Points to Success 1. Someone in a high level in the Quality Department should write the response. 2. Personnel copied on the response should include high- level management. This shows that management at the firm is aware of the issues and the commitments being made. 3. Include a cover letter or opening statement. Thank the auditor(s) for being professional, providing insight or other appropriate remarks as warranted. State the site address of the audit and the dates. 4. Always remember that you are writing the response to the auditor’s management – governmental auditing bodies as well as clients. Do not assume that the person reading the report understands the context of the observation or your reply.
  • 5. 14 Points to Success 5. Re-state the observation and reference number in the response. Typically, the observation goes directly above the response. 6. If possible, indicate the related compliant systems. This shows that you are in control and that some operations were functioning within acceptable GMP parameters. 7. If the action item is going to take some time to implement, state what will be done in the interim to be compliant with GMPs? Don’t simply indicate that actions will be taken in six months to correct the issue in which you are currently out of compliance without addressing what you will do to be compliant from the current date until the corrections are implemented.
  • 6. 14 Points to Success 8. If corrective actions have already taken place, indicate the following: • Dates implemented • Training performed (copies of training sign-up sheets included) • Copies of Purchase Orders, installation work, etc. • Copies of updated SOPs – indicating what was changed. 9. Define how enhancements will prevent recurrence of the issue observed. Don’t assume that the reader will understand this fact. 10. Explain what will be done to expand, enhance or streamline the compliance system.
  • 7. 14 Points to Success 11. Don’t forget about training. Allow sufficient time to implement changes to incorporate training that may include proficiency testing. 12. Describe how the firm will monitor the progress and effectiveness of the corrective actions. 13. It may be helpful to explain that despite the issues noted, there has never been an issue. It is not advisable to use this response tactic each time but it can be advantageous for critical observations to state something on the order of “…the product has always met predetermined quality parameters…” 14. Revise, revise, revise. Allow other people not directly involved with the audit to review and comment on the response. They may have insight on response wording that would assist in clarification or strengthening of points.
  • 8. 7 Actions to Avoid Although the following information is not an exhaustive list, there are some strategies taken by firms that indicate to an auditor the firm’s unwillingness to change or inability to make appropriate corrective actions. If a firm does not have the capability, time or experience to respond appropriately to an audit (especially a government audit), a prime directive should be to seek outside assistance. AVOID – At all costs!
  • 9. Pathway to Disaster 1. During the closeout or in the response letter, argue every point in that “they are not appropriate” or “we have never had an issue with this point from other auditors”. This is called a “scorched earth” policy and will ensure that the auditor has a strong message of non-compliance to the auditor body. 2. State that the corrective actions being requested will “put the firm out of business” or “drive jobs to a foreign country”. It is a scare tactic that has been used for at least 20 years and has not proven to be the case. 3. The “rain forest” or overwhelming response. Include massive amounts of data that is not warranted with the hopes that the reviewer will be “impressed” with the work. This type of response sends an immediate warning signal to the auditor that issues are being glossed over.
  • 10. Pathway to Disaster 4. Implement changes immediately. Either during the closeout meeting or with a quick response, all changes have been implemented for complex issues. If the issue is simple, great – no problem. However, for complex observations, a rapid response indicates that the firm has taken a knee-jerk reaction and implemented corrective actions without thinking of the root cause. 5. Not responding to the audit. Actions may be taken but no formal letter is sent indicating what was performed. This approach indicates that the firm does not take the audit seriously.
  • 11. Pathway to Disaster 6. The enigmatic response. The firm indicates that actions are going to be taken but does not address what these actions include. Such an example would include: Actions Taken – Records were updated. When? How were they updated? 7. Promise without substance. Similar to the enigmatic response, this approach does not indicate any specifics. An example includes: Deficiency – Detailed investigation not performed in a timely manner. Response – Investigations will be carried out in a timely manner.
  • 12. Assess Systemically Resolve Issues or Plan to Resolve – Systemically, across all sites Finish the Response – If serious enough, follow-up with your district office Verify – that the resolutions worked The FDA 483 – Phases to Resolve Phase 4 Phase 1 Phase 2 Phase 3
  • 13. The Choice is Yours! Work diligently now or face serious issues in the future
  • 14. Questions? More Information? Compliance Insight, Inc. www.Compliance-Insight.com 513-860-3512 FDA483Team@Compliance-Insight.com We have a significant source of information to help you on dealing FDA 483’s – Contact us for a free consultation.